35 results on '"Porter, John B."'
Search Results
2. SLN124, a GalNAc conjugated 19‐mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers
3. Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept
4. Early‐onset reduced bone mineral density in patients with pyruvate kinase deficiency
5. The clinical relevance of detectable plasma iron species in iron overload states and subsequent to intravenous iron‐carbohydrate administration
6. Response to Cabantchik and Hershko commentary “Plasma nontransferrin bound iron–nontransferrin bound iron revisited: Implications for systemic iron overload and in iv iron supplementation”
7. Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias
8. Iron Through the Prism of Haematology
9. Influence of patient‐reported outcomes on the treatment effect of deferasirox film‐coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis
10. Predicting serum ferritin levels in patients with iron overload treated with the film-coated tablet of deferasirox during the ECLIPSE study
11. New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study
12. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia
13. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions
14. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation
15. Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment
16. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study
17. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia
18. Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients
19. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: the safety profile of deferasirox
20. High index of suspicion for early diagnosis of alendronate‐induced stage zero osteonecrosis of jaw in thalassaemia major
21. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients
22. Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome
23. Symptoms of depression and anxiety in patients with thalassemia: Prevalence and correlates in the thalassemia longitudinal cohort
24. Deferasirox—current knowledge and future challenges
25. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload
26. Concepts and goals in the management of transfusional iron overload
27. Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron
28. Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major
29. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance
30. Practical management of iron overload
31. Simplified flow cytometric method for fetal hemoglobin containing red blood cells
32. The metabolites of nitric oxide in sickle‐cell disease
33. Subcellular distribution of desferrioxamine and hydroxypyridin‐4‐one chelators in K562 cells affects chelation of intracellular iron pools
34. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage
35. New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.